Presentation is loading. Please wait.

Presentation is loading. Please wait.

Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell–Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation 

Published byJens Johannsen Modified over 5 years ago

Similar presentations

Presentation on theme: "Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell–Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation "— Presentation transcript:

1 Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell–Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation  Amir A. Toor, Roy T. Sabo, Harold M. Chung, Catherine Roberts, Rose H. Manjili, Shiyu Song, David C. Williams, Wendy Edmiston, Mandy L. Gatesman, Richard W. Edwards, Andrea Ferreira-Gonzalez, William B. Clark, Michael C. Neale, John M. McCarty, Masoud H. Manjili  Biology of Blood and Marrow Transplantation  Volume 18, Issue 5, Pages (May 2012) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 AUC for ROC curves for GVHD status, remission status, and whole blood chimerism against the ddCD3 group. The table lists ddCD3 cutoff values calculated from the sum of AUCs for different ROC curves. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

3 Figure 2 (A) Kaplan-Meier survival curve for overall survival time, comparing the high ddCD3 (>110) and low ddCD3 (<110) groups. (B) Kaplan-Meier survival curve for progression-free survival time, comparing the high ddCD3 and low ddCD3 groups. (C) Kaplan- Meier failure curve for time to relapse, comparing the high ddCD3 and low ddCD3 groups. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

4 Figure 3 (A) T cell chimerism trend in patients with MC and ddCD3 <110/μL. (B) T cell chimerism trend in patients with MC and ddCD3 >110/μL. (C) Trends in ddCD3 cell count over time in the high and low recovery groups. (D) Effect of ddCD3 count at 8 weeks on T cell chimerism at 24 weeks. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

5 Figure 4 Effect of immunosuppression withdrawal on granulocyte chimerism in the high ddCD3 and low ddCD3 groups. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Favorable Outcomes in Patients with High Donor-Derived T Cell Count after In Vivo T Cell–Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation "

Similar presentations

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,

Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation  Nirali N. Shah, Michael J. Borowitz,
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma (PCNSL) in First Complete Remission (CR1) 
Ulas D. Bayraktar, Denái R. Milton, Elizabeth J

Ulas D. Bayraktar, Denái R. Milton, Elizabeth J
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation  David Stephen Shulman, Wendy B. London, Dongjing.
Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.

Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.

Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.
Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation.

Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation.
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI  Alix O’Meara, Jörg Halter, Dominik.
Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation  Aaron Gerds, Mary Fox-Geiman,

Randomized Phase III Trial of Pegfilgrastim versus Filgrastim after Autologus Peripheral Blood Stem Cell Transplantation  Aaron Gerds, Mary Fox-Geiman,
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.

The Prognostic Value of YKL-40 Concentrations in Nonmyeloablative Conditioning Allogeneic Hematopoietic Cell Transplantation  Anne Mette Mørup, Brian.
In Silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem Cell Transplant Donor-Recipient Pairs  Maximilian Jameson-Lee,

In Silico Derivation of HLA-Specific Alloreactivity Potential from Whole Exome Sequencing of Stem Cell Transplant Donor-Recipient Pairs  Maximilian Jameson-Lee,
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity.

Dynamical System Modeling to Simulate Donor T Cell Response to Whole Exome Sequencing-Derived Recipient Peptides Demonstrates Different Alloreactivity.
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Similar presentations

Ads by Google